VERV (Verve Therapeutics) Total Stockholders Equity : $493.40 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Verve Therapeutics Total Stockholders Equity?

Verve Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $493.40 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Verve Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 was $5.56. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Verve Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.14.

Verve Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Verve Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verve Therapeutics Total Stockholders Equity Chart

Verve Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

-63.91

357.35

550.93

599.50

493.40

Verve Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															599.50	583.07	546.09	508.55	493.40

Verve Therapeutics (NAS:VERV) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Verve Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(493.4	-	0)	/	88.758
	=	5.56

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Verve Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.442	+	59.541)	/	493.4
	=	0.14

Verve Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Verve Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Verve Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verve Therapeutics Inc (NAS:VERV) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Brookline Avenue, Suite 601, Boston, MA, USA, 02215

Website

https://www.vervetx.com

Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.

Executives

Allison Dorval	officer: Chief Financial Officer	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Andrew D. Ashe	officer: See Remarks	C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Joan Nickerson	officer: Chief Administrative Officer	C/O VERVE THERAPEUTICS, INC., 201 BROOKLINE AVENUE, SUITE 601, BOSTON MA 02215
Krishna Yeshwant	director, 10 percent owner	C/O GOOGLE VENTURES 2011, L.P., 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Fred T. Fiedorek	officer: Chief Medical Officer	55 BALDWIN LANE, PRINCETON NJ 08540
Andrew Bellinger	officer: Chief Scientific Officer	500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Gv 2017 Gp, L.l.c.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Alphabet Inc.	other: Member of 10% Group	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Sekar Kathiresan	director, 10 percent owner, officer: Chief Executive Officer	500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Lonnel Coats	director	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Fmr Llc	10 percent owner, other: See Remark 1	245 SUMMER STREET, BOSTON MA 02210
Alexander Cumbo	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Burt A Adelman	director, 10 percent owner	DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Logos Global Management Lp	10 percent owner	1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO CA 94129